Discover MCTs and Choose the Right Design to Progress Your Preclinical Study
Traditional oncology drug development strategies are failing – oncology agents have a higher attrition rate than other therapeutic areas, with activity rather than safety being the main clinical trial stumbling block. There is a clear need for improved methods and more predictive models, to fully understand preclinically which subgroups of patients will respond and the reasons why, to improve chances of clinical success.
Mouse Clinical Trials (MCTs) using patient-derived xenograft (PDX) models are a key example of a more predictive and translatable approach. PDXs are recognized as the most predictive preclinical model, closely recapitulating patient molecular and histopathology, as well as treatment response. Utilizing large cohorts of these models in a small number of animals within an MCT closely reflects clinical trials, providing a better perspective of patient-to-patient heterogeneity while assessing treatment response.
MCTs also provide the perfect framework for biomarker discovery, which is growing ever more important as personalized medicine progresses, and biomarkers become a crucial component in clinical trial success.
Download This White Paper To Understand:
- The main features and drawbacks to 0+1 and 1+1 MCTs and which may be best for any given study
- How the type of MCT used depends on the hypothesis being tested – with either targeted approaches (studying one target/mutation across many indications) or indication approaches (studying one cancer type with potentially multiple drive mutations) available
- How MCTs leverage patient-to-patient variability for biomarker discovery